Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The FDA has approved Zanvastro, the first disease-modifying treatment for Alexander disease — a rare, often fatal neurological disorder affecting fewer than 1 in a million people. The drug, developed through over 30 years of research, uses antisense oligonucleotide technology to reduce harmful protein buildup in the brain. Clinical trials showed stabilization of motor function and movement improvements in some patients.
After more than three decades of research, the FDA has approved Zanvastro — the first drug designed to directly target Alexander disease, an extremely rare and progressive neurological disorder that can impair movement, cognition, and vital functions like breathing and heart rate. Until now, patients had no options beyond symptom management.
The breakthrough traces back to an accidental discovery in the late 1990s, when researchers at the University of Wisconsin-Madison engineered mice that overproduced glial fibrillary acidic protein (GFAP) — and unexpectedly developed brain lesions identical to those seen in Alexander disease. That finding revealed GFAP mutations as the genetic root cause and opened the door to a targeted therapy. In partnership with Ionis Pharmaceuticals, scientists developed Zanvastro, an antisense oligonucleotide (ASO) that reduces GFAP production before it can accumulate and damage brain cells. It's administered via spinal injection every three months.
By the Numbers:
Why it matters: Zanvastro sets a landmark precedent — proving that decades of basic science research can translate into life-changing therapies for ultra-rare diseases. For Alexander disease patients and families who had no approved treatment options, this approval is a long-awaited turning point.
